Meningites Bacterianas Telma
PDF

Como Citar

1.
Marques Pinto Carvalhanas TR, de Cunto Brandileone MC, Cobo Zanella R. Meningites Bacterianas Telma. Bepa [Internet]. 31º de maio de 2005 [citado 26º de dezembro de 2024];2(17):15-26. Disponível em: https://periodicos.saude.sp.gov.br/BEPA182/article/view/38902

Resumo

 

 

PDF

Referências

-APPELBAUM, P.C. Resistance among Streptococcus pneumoniae: Implications for Drug

Selection, Clin Infect Dis 2002;34:1613-20.

BASHIR, H.E., LAUNDY, M., BOOY, R. Diagnosis and treatment of bacterial meningitis. ArchDis Child 2003; 88: 615-620.

BAQUERO, F. Pneumococcal resistance to B-lactam antibiotics: a global geographic overview.Microb. Drug Resist., 1:115-120, 1995.

BLACK, S., SHINEFIELD, H., FIREMAN, B., et al. Efficacy, safety and immunogenicity ofheptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J., 19: 187-195, 2000.

BRANDILEONE, M.C.C., DI FABIO, J.L., VIEIRA, V.S.D., et al. Geographic distribution ofpenicillin resistance of Streptococcus pneumoniae in Brazil: genetic relatedness. Microb. DrugResist., 4:209-217, 1998.6. BRANDILEONE, M.C.C., ANDRADE, A.L.S.S., DI FABIO, J.L., et al. Appropriateness of apneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, withemphasis on meningitis. J. Infect. Dis., 187:1206-1212, 2003.

CARVALHANAS, T. R. M. P. Situação epidemiológica das meningites bacterianas no Estado deSão Paulo. BEPA 2004, ano 1, nº 5. Disponível em: http://www.cve.saude.sp.gov.br. Acesso em22/4/2005.8. CAUGANT, D.A. Epidémiologie de Neisseria meningitidis, L'analyse des clones. Annales del'Institut Pasteur/Actualités. 1994;5:130-7.

CENTERS FOR DISEASE CONTROL AND PREVENTION. Control and prevention ofmeningococcal disease: recommendations of the Advisory Committee on Immunization Practices(ACIP). MMWR Morb Mortal Wkly Rep 2000;49:110.

CENTERS FOR DISEASE CONTROL AND PREVENTION. Control and prevention ofserogroup C meningococcal disease: evaluation and management of suspected outbreaks:recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR MorbMortal Wkly Rep, 46(RR-5):13-21, feb, 1997.

DIAZ, J.M., CATALAN, L., URRUTIA, M.T. et al. Trends of etiology of acute bacterialmeningitis in Chilean children from 1989 to 1998. Impact of the anti-H. influenzae type b vaccine.Rev Med Chil 2001; 129:71926.

DICKINSON, F.O., PEREZ, A E., GALINDO, M.A. et al. Impact of vaccination againstHaemophilus influenzae type b in Cuba. Rev Panam Salud Publica 2001;10:16973.

DI FABIO, J.L, CASTAÑEDA, E., AGUDELO, C.I. et al. Evolution of Streptococcuspneumoniae serotypes and PEN susceptibility in Latin America, SIREVA-Vigía Group, 1993 to1999. Pediatr. Infect. Dis. J., 20:959-977, 2001.

FOCACCIA, R. Meningites bacterianas - etioepidemiologia e meningites agudas vol. 1,cap.66.1;827-843.in: Veronesi R, Focaccia R. Tratado de Infectologia, 2ª ed., Atheneu , SãoPaulo, 2002.

FONSECA, C., MORAES, J.C., BARATA, R.B. O livro da Meningite: uma doença sob a luz dacidade. ed rev São Paulo: Segmento Farma, 2004, 201p.

IRWIN, D.J., MILLER, J.M., MILNER, P.C. et al. Community immunization programme inresponse to an outbreak of invasive Neisseria meningitidis serogroup C infection in the Trentregion of England 19951996. J Public Health Med 1997;19:16270.

KACZMARSKI, E.B. Meningococcal Disease in England and Wales. 1995. Commun Dis RepCDR Rev 1997; 7: R55-9.

LEPOW, M. L., PERKINS, B. A., HUGHES, P. A. et al. Meningococcal vaccines. In: PLOTKIN,S.A., ORENSTEIN, W. A., eds. Vaccines. 3rd ed. Philadelphia: W. B. Saunders Company, 1999, p.711-27.

MILLER, E., SALISBURY, D., RAMSAY, M.E. Planning, registration, and implementation of animmunization campaign against meningococcal serogroup C disease in the UK: a success story.Vaccines 2002;20(suppl 1):558-67.

PELTOLA, H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21stcentury: global analysis of the disease burden 25 years after the use of the polysaccharide vaccineand a decade after the advent of conjugates. Clin Microbiol Rev 2000;13:30217.

PHLS Guidelines for public health management of meningococcal disease in the UK. CommunDis Public Health 2002; 5(3): 187-204.

SCHOLTEN, R.J., POOLMAN, J.T., VALKENBURG, H.A. et al. Phenotypic and genotypicchanges in a new clone complex of Neisseria meningitidis causing disease in the Netherlands,1958 - 1990. J Infect Dis 1994; 169: 673-6.

SNAPE, M.D., POLLARD, A.J. Meningococcal polysaccharide-protein conjugate vaccines.Lancet Infect Dis, 5(1):21-30, jan, 2005.

TUNKEL, A R., HARTMAN, B.J., KAPLAN, S.L. et al. Practice Guidelines for the Managementof Bacterial Meningitis. Clin Infect Dis 2004;39:1267-84

UDUMAN, S.A , ADEYEMI, E., EL-KHADIR, A. et al. A. Haemophilus influenzae type b stillremains a leading cause of meningitis among unvaccinated childrena prospective CSF analysisstudy. J Trop Pediatr 2000;46:3314.26. WORLD HEALTH ORGANIZATION. Control of epidemic meningococcal infection: WHOpractical guidelines. Geneva: WHO, 2000.

ZANELLA, R.C., CASAGRANDE, S.T., BRANDILEONE, M.C.C. et al. Characterization ofHaemophilus influenzae Isolated from Invasive Disease in Brazil from 1990 to 1999. Microbial DrugResistance 2002, 8 (1): 67-71.

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2005 Telma Regina Marques Pinto Carvalhanas, Maria Cristina de Cunto Brandileone, Rosemeire Cobo Zanella

Downloads

Não há dados estatísticos.

Métricas

Carregando Métricas ...